

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/521,513-Conf. #2848	
			Filing Date	November 18, 2005	
			First Named Inventor	Roy R. Lobb	
			Art Unit	1647	
			Examiner Name	J. Seharaseyon	
Sheet	1	of	1	Attorney Docket Number	BII-001.01

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>7</sup>
	CA	Ai-Wakeel et al., "Role of Interferon- $\alpha$ in the Treatment of Primary Glomerulonephritis," American Journal of Kidney Diseases, 33(6):1142-1146 (1999)				
	CB	Anonymus, "Kidney Disease of Diabetes," National Institutes of Health, On-line, pp.1-8 (2008), Retrieved from Internet: URL: <a href="http://kidney.niddk.nih.gov/kudiseases/pubs/pdf/kdd.pdf">http://kidney.niddk.nih.gov/kudiseases/pubs/pdf/kdd.pdf</a>				
	CC	Garini et al., "Interferon- $\alpha$ in Combination With Ribavirin as Initial Treatment for Hepatitis C Virus-Associated Cryoglobulinemic Membranoproliferative Glomerulonephritis," American Journal of Kidney Diseases, 38(6):E35 1-5 (2001)				
	CD	Nishino et al., Journal of Japanese Society of Nephrology, August 25, 1998, 40(6):406 (abstract)				√
	CE	Takahashi et al., Clinics and Drug Therapy, April 1, 2001, 20(4):421-422 (abstract)				√
	CF	Weening et al., "The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited," Journal of the American Society of Nephrology, 15(2):241-250 (2004)				

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.